Free Submission Public Relations & NewsPR-inside.com
Home
Deutsch English

Finance
EpiCast Report: Pancreatic Cancer - Epidemiology Forecast to 2022

Global pancreatic cancer market: US & Germany have highest number of incident cases


Print article Print article
© companiesandmarkets.com

companiesandmarkets.com
companiesandmarkets.com
2014-04-25 08:07:01 - EpiCast Report: Pancreatic Cancer - Epidemiology Forecast to 2022 - a new market research report on companiesandmarkets.com

Pancreatic cancer is one of the most fatal cancers around the world, with the highest incidence and mortality rates found in developed countries (Michaud, 2004). The risk of developing pancreatic cancer is associated with increasing age, as more than 75% of pancreatic cancer patients are over the age of 60 years (SEER Cancer Statistics Review, 2012). Tobacco smoking is one of the most common risk factors for pancreatic cancer, as smokers have a two-fold increased risk of developing the disease compared with nonsmokers (Lowenfels and Maisonneuve, 2006). Due to the short survival period and high mortality for pancreatic cancer, patients with the disease are less likely to suffer from comorbidities than patients with other types of cancer.

North America and western

 

 

Europe have the highest incidence of pancreatic cancer compared with the rest of the world. The fatal nature of pancreatic cancer keeps the survival rates low and the duration of illness short. The low survival rate associated with pancreatic cancer is caused by the complexity of the disease, along with diagnosis usually occurring during the advanced stages, as the early symptoms typically go unnoticed. In the US, the five-year survival rate of pancreatic cancer is 4.8%, while the 10-year survival rate is only 3.6%; these survival rates showcase that the majority of pancreatic cancer mortality occurs within the first five years of diagnosis (Ries et al., 2007).

It is forecast that the US and Germany will have the highest number of incident cases of pancreatic cancer in 2022, with 53,610 and 27,629 cases, respectively. Our epidemiologists also expect that the number of prevalent cases of pancreatic cancer in the 6MM covered will increase during the forecast period (2012–2022) to a total of 59,675 cases. The stage at diagnosis for pancreatic cancer is correlated with the availability of screening tests and the ability to identify early symptoms. Due to the inability to identify early indications of the illness, pancreatic cancer cases are most commonly diagnosed in Stage IV. Greater research in prevention and early diagnostic testing can help reduce the incidence of the disease. Through early detection, it may be possible to stop the spread of the cancer to other organs and decrease the overall mortality.

Click for report details: www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Market Research Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Market ..

Browse all Healthcare and Medical Company Profile Reports www.companiesandmarkets.com/Market/Healthcare-and-Medical/Compan ..

Browse all Latest Market Research Reports www.companiesandmarkets.com/Market/All/Market-Research?aCode=f3f ..

About Us
Companiesandmarkets.com is a leading online business information aggregator with over 300,000 market reports and company profiles available to our clients. Our extensive range of reports are sourced from the leading publishers of business information and provide clients with the widest range of information available. In terms of company profiles, Companiesandmarkets.com’s online database allows clients access to market and corporate information to over 100,000 different companies. We provide clients with a fully indexed database of information where clients can find specific market reports on their niche industry sectors of interest.


Author:
Mike King
e-mail
Web: www.companiesandmarkets.com
Phone: London: +44 (0) 203 086 8600

Disclaimer: If you have any questions regarding information in these press releases please contact the company added in the press release. Please do not contact pr-inside. We will not be able to assist you. PR-inside disclaims contents contained in this release.
Latest News
Read the Latest News
www.newsenvoy.com

 


Terms & Conditions | Privacy | About us | Contact PR-inside.com